- Home
- EHC vs PCVX Comparison
EHC vs PCVX Comparison
Compare EHC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHC
- PCVX
- Stock Information
- Founded
- EHC 1983
- PCVX 2013
- Country
- EHC United States
- PCVX United States
- Employees
- EHC N/A
- PCVX N/A
- Industry
- EHC Hospital/Nursing Management
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- EHC Health Care
- PCVX Health Care
- Exchange
- EHC Nasdaq
- PCVX Nasdaq
- Market Cap
- EHC 8.7B
- PCVX 12.5B
- IPO Year
- EHC 1986
- PCVX 2020
- Fundamental
- Price
- EHC $92.58
- PCVX $114.13
- Analyst Decision
- EHC Strong Buy
- PCVX Strong Buy
- Analyst Count
- EHC 7
- PCVX 7
- Target Price
- EHC $99.14
- PCVX $147.50
- AVG Volume (30 Days)
- EHC 449.2K
- PCVX 1.4M
- Earning Date
- EHC 10-24-2024
- PCVX 11-04-2024
- Dividend Yield
- EHC 0.74%
- PCVX N/A
- EPS Growth
- EHC 25.88
- PCVX N/A
- EPS
- EHC 3.92
- PCVX N/A
- Revenue
- EHC $5,070,900,000.00
- PCVX N/A
- Revenue This Year
- EHC $11.83
- PCVX N/A
- Revenue Next Year
- EHC $9.01
- PCVX N/A
- P/E Ratio
- EHC $23.55
- PCVX N/A
- Revenue Growth
- EHC 10.86
- PCVX N/A
- 52 Week Low
- EHC $57.55
- PCVX $44.20
- 52 Week High
- EHC $94.38
- PCVX $119.50
- Technical
- Relative Strength Index (RSI)
- EHC 60.32
- PCVX 79.93
- Support Level
- EHC $90.43
- PCVX $77.21
- Resistance Level
- EHC $92.90
- PCVX $119.50
- Average True Range (ATR)
- EHC 1.48
- PCVX 4.33
- MACD
- EHC -0.07
- PCVX 2.90
- Stochastic Oscillator
- EHC 60.67
- PCVX 87.30
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.